Gilead Sciences’ Remdesivir Data Release Brings Much Needed Relief for Patients and Investors
For years, Gilead Sciences' (NASDAQ: GILD) stock price has been rather disappointing for investors hoping for long-term capital appreciation. While shares do boast an impressive 3.63% dividend yield, the company's revenues have experienced an enormous decline from 2015 onwards, falling over $10 billion in the past four years as patients cured of hepatitis C no longer needed drugs from Gilead.
In a twist of fate, however, a once little-known drug manufactured by the company during the Ebola virus pandemic may hold the cure to the current coronavirus outbreak, and thereby significantly improve the company's bottom line.
Source Fool.com